课题基金 / 基金详情

CATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSION

CATEGORIZATION OF WILMS TUMOR BY GENETIC EXPRESSION
根据基因表达对肾母细胞瘤进行分类
批准号:
6514739
负责人:
Elizabeth J Perlman
金额:
$25.81万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-18 至 2006-11-30

项目摘要

项目成果

Elizabeth J Perlman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Applicant's Description) Wilms tumor represents the most common renal neoplasm of childhood. Remarkable success has been achieved in the therapy of WT through the National Wilms Tumor Study Group (NWTS). Despite the responsiveness of most WT to adjuvant chemotherapy, some tumors are unresponsive and result in tumor progression and death. Most tumors lack distinctive histologic or clinical features to enable targeting with more or less aggressive chemotherapy. Recognizing biologically distinctive subsets of WT may be useful for predicting clinical behavior and targeting therapy. The goal of this project is to identify molecular categories of WT that have predictable clinical properties, including propensity to metastasize and response to therapy. We hypothesize that gene expression profiles will aid in the recognition of these categories. AIM ONE: To identify candidate marker genes that are differentially expressed: Using commercially available cDNA macro-arrays, we will comprehensively analyze gene expression in a small group of Wilms tumors. A subset of genes whose expression varies throughout these tumors will be identified. AIM TWO: To identify molecular categories of Wilms tumor based upon the expression of candidate marker genes identified in Aim One: Utilizing custom cDNA microarrays approximately 200-300 pathologically, clinically and genetically characterized WT will be analyzed. Using computationally assisted methods, profiles of gene expression that define molecular categories of Wilms tumors will be identified. AIM THREE: To verify, test, and model the new molecular categories of Wilms tumor and to examine these new categories in their clinical, pathologic, and genetic context. Each molecular category will be analyzed and validated for clinical, pathologic and genetic features using the extensive resources of the NWTS. Genes predictive of molecular categories will be verified using in situ hybridization or immunohistochemistry. A model categorization will be proposed and tested on 200 additional Wilms tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epigenetic and clinical impact of SMARCB1 loss in cancer
Epigenetic and clinical impact of SMARCB1 loss in cancer
Validation of copy number changes by MLPA as predictors of relapse in Wilms tumor
Validation of copy number changes by MLPA as predictors of relapse in Wilms tumor
海外基金